Skip to main content
Erschienen in:

01.10.2005 | Leitthema

Weichteilsarkome im Kindesalter

Diagnostik und Therapie

verfasst von: Prof. Dr. E. Koscielniak, T. Klingebiel, A. Schuck, I. Leuschner

Erschienen in: Die Onkologie | Ausgabe 10/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei Weichteilsarkomen (WTS) handelt es sich um eine seltene, in ihrer Klinik und Biologie sehr heterogene Gruppe maligner Tumoren. Das häufigste bei Kindern auftretende WTS ist das Rhabdomyosarkom (RMS). Die multizentrischen Therapieoptimierungsstudien, hier auch die Cooperative Weichteilsarkom Studie CWS der GPOH, haben entscheidend zur Verbesserung der Prognose von Kindern mit WTS beigetragen. Die Reihenfolge wie auch die Durchführung der einzelnen Therapiemodalitäten (Chirurgie, Chemotherapie, Radiotherapie) hängt von der Tumorgröße, Histologie, Lokalisation und dem Alter des Patienten ab. Die rezidivfreie Überlebensrate nach 5 Jahren für alle Patienten mit „RMS-artigen“ Tumoren (RMS, EES, PNET, SySA) beträgt 50–80% (RMS 70%, EES/PNET 50%, SySa 70–80%).
Literatur
1.
Zurück zum Zitat Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D (2004) Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Pädiatr 216:176–182 Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D (2004) Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Pädiatr 216:176–182
2.
Zurück zum Zitat Alava ED (2000) Molecular biology of the Ewing‚s Sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 18:204–213PubMed Alava ED (2000) Molecular biology of the Ewing‚s Sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 18:204–213PubMed
3.
Zurück zum Zitat Barr F (1997) Molecular genetics and pathogenesis of rahbdomyosarcoma. J Pediatr Hematol/Oncol 19:483–491 Barr F (1997) Molecular genetics and pathogenesis of rahbdomyosarcoma. J Pediatr Hematol/Oncol 19:483–491
4.
Zurück zum Zitat Bisogno G, Ferrari A, Bergeron C (2005) The IVADo regimen-A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma. Cancer 103:1719–1724CrossRefPubMed Bisogno G, Ferrari A, Bergeron C (2005) The IVADo regimen-A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma. Cancer 103:1719–1724CrossRefPubMed
5.
Zurück zum Zitat Bramwell V, Rouesse J, Steward W (1994) Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 12:1137–1149PubMed Bramwell V, Rouesse J, Steward W (1994) Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 12:1137–1149PubMed
6.
Zurück zum Zitat Breneman JC, Lyden E, Pappo AS (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78–84CrossRefPubMed Breneman JC, Lyden E, Pappo AS (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78–84CrossRefPubMed
7.
Zurück zum Zitat Carli M, Colombatti R, Oberlin O (1999) High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17:2796–2803PubMed Carli M, Colombatti R, Oberlin O (1999) High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17:2796–2803PubMed
8.
Zurück zum Zitat Carli M, Passone E, Perilongo G, Bisogno G (2003) Ifosfamide in pediatric solid tumors. Oncology 65:99–104CrossRefPubMed Carli M, Passone E, Perilongo G, Bisogno G (2003) Ifosfamide in pediatric solid tumors. Oncology 65:99–104CrossRefPubMed
9.
Zurück zum Zitat Carli M, Sotti G, Alaggio R, Stevens MCG (2004) Soft Tissue Sarcomas. In: Pinkerton R PP, Pieters R, ed. Pediatric Oncology. London: Arnold Carli M, Sotti G, Alaggio R, Stevens MCG (2004) Soft Tissue Sarcomas. In: Pinkerton R PP, Pieters R, ed. Pediatric Oncology. London: Arnold
10.
Zurück zum Zitat Carli M, Colombatti R, Oberlin O (2004) European intergroup studies (MMT4–89 and MMT4–91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22:4787–4794CrossRefPubMed Carli M, Colombatti R, Oberlin O (2004) European intergroup studies (MMT4–89 and MMT4–91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22:4787–4794CrossRefPubMed
11.
Zurück zum Zitat Coindre JM, Nguyen BB, Bonichon F, de Mascarel I, Trojani M (1988) Histopathologic grading in spindle cell soft tissue sarcomas. Cancer 61:2305–2309PubMed Coindre JM, Nguyen BB, Bonichon F, de Mascarel I, Trojani M (1988) Histopathologic grading in spindle cell soft tissue sarcomas. Cancer 61:2305–2309PubMed
12.
Zurück zum Zitat Crist WM, Anderson JR, Meza JL (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102PubMed Crist WM, Anderson JR, Meza JL (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102PubMed
13.
Zurück zum Zitat Crist W, Gehan EA, Ragab AH (1995) The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610–630PubMed Crist W, Gehan EA, Ragab AH (1995) The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610–630PubMed
14.
Zurück zum Zitat Joensuu H, Roberts PJ, Sarlomo-Rikala M (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMed Joensuu H, Roberts PJ, Sarlomo-Rikala M (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMed
15.
Zurück zum Zitat Kampe CE, Rosen G, Eilber F (1994) Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer 72:2161–2169 Kampe CE, Rosen G, Eilber F (1994) Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer 72:2161–2169
16.
Zurück zum Zitat Kawaguchi S, Wada T, Ida K (2005) Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 3:1CrossRefPubMed Kawaguchi S, Wada T, Ida K (2005) Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 3:1CrossRefPubMed
17.
Zurück zum Zitat Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338:153–160CrossRefPubMed Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M (1998) SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338:153–160CrossRefPubMed
18.
Zurück zum Zitat Koscielniak E, Dilloo D (2002) Definition of the high risk patients: the EBMT-CWS experience and CWS proposal for a therapeutic strategy for high risk sarcoma patients. Bone Marrow Transplant 30:33–34 Koscielniak E, Dilloo D (2002) Definition of the high risk patients: the EBMT-CWS experience and CWS proposal for a therapeutic strategy for high risk sarcoma patients. Bone Marrow Transplant 30:33–34
19.
Zurück zum Zitat Koscielniak E, Gross-Wieltsch U, Treuner J (2005) Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 23:242–24419CrossRefPubMed Koscielniak E, Gross-Wieltsch U, Treuner J (2005) Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 23:242–24419CrossRefPubMed
20.
Zurück zum Zitat Koscielniak E, Harms D, Henze G (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17:3706–3719PubMed Koscielniak E, Harms D, Henze G (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17:3706–3719PubMed
21.
Zurück zum Zitat Koscielniak E, Klingebiel TH, Peters C (1997) Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19:227–231CrossRefPubMed Koscielniak E, Klingebiel TH, Peters C (1997) Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19:227–231CrossRefPubMed
22.
Zurück zum Zitat Koscielniak E, Rodary C, Flamant F (1992) Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 20:209–214PubMed Koscielniak E, Rodary C, Flamant F (1992) Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 20:209–214PubMed
23.
Zurück zum Zitat Ladenstein R, Hartmann O, Koscielniak E, Philip T (2004) Megatherapy with stem cell rescue in solid tumors. In: Pinkerton R PP, Pieters R, ed. Paediatric Onclogy. London: Arnold; 539–569 Ladenstein R, Hartmann O, Koscielniak E, Philip T (2004) Megatherapy with stem cell rescue in solid tumors. In: Pinkerton R PP, Pieters R, ed. Paediatric Onclogy. London: Arnold; 539–569
24.
Zurück zum Zitat Ladenstein R, Treuner J, Koscielniak E (1993) Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 71:3647–3655PubMed Ladenstein R, Treuner J, Koscielniak E (1993) Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 71:3647–3655PubMed
25.
Zurück zum Zitat Misawa A HH, Tsuchiya K, Iehara T, Sawada T, Sugimoto T (2003) Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 151–15525 Misawa A HH, Tsuchiya K, Iehara T, Sawada T, Sugimoto T (2003) Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 151–15525
26.
Zurück zum Zitat Newton WA Jr GE, Webber BL et al. (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects—an Intergroup Rhabdomysoarcoma Study. Cancer 76:1073–1085PubMed Newton WA Jr GE, Webber BL et al. (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects—an Intergroup Rhabdomysoarcoma Study. Cancer 76:1073–1085PubMed
27.
Zurück zum Zitat Okcu MF, Despa S, Choroszy M (2001) Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol 37:90–96CrossRefPubMed Okcu MF, Despa S, Choroszy M (2001) Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol 37:90–96CrossRefPubMed
28.
Zurück zum Zitat Raney RB (2005) Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 27:207–211CrossRefPubMed Raney RB (2005) Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 27:207–211CrossRefPubMed
29.
Zurück zum Zitat Rosen G, Forscher C, Lowenbraun S (1994) Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:2506–2511PubMed Rosen G, Forscher C, Lowenbraun S (1994) Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:2506–2511PubMed
30.
Zurück zum Zitat Rubin BP, Schuetze SM, Eary JF (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591CrossRefPubMed Rubin BP, Schuetze SM, Eary JF (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591CrossRefPubMed
31.
Zurück zum Zitat Schramm A, Apostolov O, Sitek B, Pfeiffer K, Stühler K, Meyer HE, Havers W, Eggert A (2003) Proteomics: Techniques and applications in cancer research. Klin Pädiatr 215:293–297 Schramm A, Apostolov O, Sitek B, Pfeiffer K, Stühler K, Meyer HE, Havers W, Eggert A (2003) Proteomics: Techniques and applications in cancer research. Klin Pädiatr 215:293–297
32.
Zurück zum Zitat Schulte JH, Schramm A, Pressel T, Klein-Hitpass L, Kremens B, Eils J, Havers W, Eggert A (2003) Microarray-analysis: A new approach to study the molecular mechanisms of thermo-chemotherapy. Klin Pädiatr 215:298–302 Schulte JH, Schramm A, Pressel T, Klein-Hitpass L, Kremens B, Eils J, Havers W, Eggert A (2003) Microarray-analysis: A new approach to study the molecular mechanisms of thermo-chemotherapy. Klin Pädiatr 215:298–302
33.
Zurück zum Zitat Siebenrock KA, Hertel R, Ganz R (2000) Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg 120:65–69PubMed Siebenrock KA, Hertel R, Ganz R (2000) Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg 120:65–69PubMed
34.
Zurück zum Zitat Staege MS, Hattenhorst UE, Neumann I, Hutter C, Foja S, Burdach S (2003) DNA-Microarrays as tools for the identification of tumor specific gene expression profiles: Applications in tumor biology, diagnosis and therapy. Klin Pädiatr 215:135–138 Staege MS, Hattenhorst UE, Neumann I, Hutter C, Foja S, Burdach S (2003) DNA-Microarrays as tools for the identification of tumor specific gene expression profiles: Applications in tumor biology, diagnosis and therapy. Klin Pädiatr 215:135–138
35.
Zurück zum Zitat Stegmeier S, Leuschner I, Aakcha-Rudel E, Münch P, Kazanowska B, Bekassy A, Treuner J, Koscielniak E (2004) Identification of various exon combinations of the ews/fli1 translocation: An optimized PT-PCR method for paraffin embedded tissue. A report by the CWS-Study Group. Klin Pädiatr 216:315–322 Stegmeier S, Leuschner I, Aakcha-Rudel E, Münch P, Kazanowska B, Bekassy A, Treuner J, Koscielniak E (2004) Identification of various exon combinations of the ews/fli1 translocation: An optimized PT-PCR method for paraffin embedded tissue. A report by the CWS-Study Group. Klin Pädiatr 216:315–322
36.
Zurück zum Zitat Stevens MC, Rey A, Bouvet N (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed Stevens MC, Rey A, Bouvet N (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed
37.
Zurück zum Zitat Treuner J (2003) Interim Report of the CWS-96 Study: Results of the tretament for soft tissue sarcomas in childhood Treuner J (2003) Interim Report of the CWS-96 Study: Results of the tretament for soft tissue sarcomas in childhood
38.
Zurück zum Zitat Wessalowski R, Schneider DT, Mils O et al. (2003) An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Pädiatr 215:303–309 Wessalowski R, Schneider DT, Mils O et al. (2003) An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Pädiatr 215:303–309
Metadaten
Titel
Weichteilsarkome im Kindesalter
Diagnostik und Therapie
verfasst von
Prof. Dr. E. Koscielniak
T. Klingebiel
A. Schuck
I. Leuschner
Publikationsdatum
01.10.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 10/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0928-z

Weitere Artikel der Ausgabe 10/2005

Der Onkologe 10/2005 Zur Ausgabe

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.